Appendix Table C44Nasal symptom outcomes: change from baseline–intranasal corticosteroid versus leukotriene receptor antagonist

Author, YearDrug, Dose/DayN/nTime, weeksCongestionpRhinorrheapSneezingpItchingpTNSSp
Lu, 2009 (Trial 1)Beclomethasone dipropionate 400 mcg173/1722-0.7 (-0.78, -0.61)≤0.01
Montelukast 10 mg112/1112-0.36 (-0.46, -0.25)
Martin, 2006Fluticasone propionate 200 mcg367/3642-31.1 (1.2)<0.01-32.9 (1.2)<0.01-33.5 (1.2)<0. 01-32.8 (1.2)<0.001-130.2 (4.7)<0.01
Montelukast 10 mg369/3662-23.1 (1.2)-23.5 (1.2)-24.9 (1.2)-25.0 (1.2)-96.6 (4.7)
Nathan, 2005Fluticasone propionate 200 mcg291/2912-24.0 (1.6)<0.01-26.5 (1.6)<0.01-25.4 (1.6)<0.01-24.0 (1.6)<0.001-99.1 (5.8)<0.01
Montelukast 10 mg282/2822-16.7 (1.6)-18.7 (1.7)-19.1 (1.7)-18.7 (1.6)-73.0 (6.0)
Pullerits, 2002Fluticasone propionate 200 mcg13a2-0.1 cNS
Montelukast 10 mg16a20.7 c
Ratner, 2003Fluticasone propionate 200 mcg353/3532-31.4 (1.2)<0.01-32.6 (1.2)<0.01-33.7 (1.2)<0.01-32.7 (1.2)<0.001-130.3 (4.7)<0. 01
Montelukast 10 mg352/3522-22.7 (1.2)-24.3 (1.2)-23.7 (1.2)-23.2 (1.2)-94.0 (4.7)
Nathan, 2005Fluticasone propionate 200 mcg291/2914-29.0 (1.7)<0.01-30.7 (1.7)<0.01-29.3 (1.7)<0.01-28.8 (1.7)<0.001-117.0 (6.2)<0.01
Montelukast 10 mg282/2824-20.7 (1.7)-22.7 (1.7)-23.1 (1.7)-22.8 (1.7)-89.1 (6.4)
Pullerits, 2002Fluticasone propionate 200 mcg13a5 b1.1 dNS
Montelukast 10 mg16a5b2.5 d
Pullerits, 2002Fluticasone propionate 200 mcg13a8 c-0.4 d<0.05
Montelukast 10 mg16a8c0.3 d

N/n = Number of patients randomized/number of patients analyzed; NS = non-significant; TNSS = total nasal symptom score.

Values are mean (standard error) change from baseline. Entries for each outcome represent the mean change from baseline symptom score. Nathan, 2005, Nathan, 2005, and Ratner, 2003 used a 0 (no symptoms) to 100 (most severe symptoms) VAS to rate each symptom, then summed the symptom scores for TNSS (maximum, 400). Pullerits, 2002 used a 0 (no symptoms) to 4 (severe symptoms) categorical scale for each symptom, then summed the scores for TNSS (maximum, 16). Lu, 2009 used a 0 (no symptoms) to 3 (severe symptoms) to rate each symptom, then averaged the symptom scores for TNSS (maximum, 3).

a

Only patients randomized are reported.

b

Average for interval from 3-5 weeks.

c

Average for interval from 6-8 weeks.

d

Calculated by report author from pre/post data reported.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.